Literature DB >> 19517427

Analysis of the constituents in rat plasma after oral administration of Shexiang Baoxin pill by HPLC-ESI-MS/MS.

Peng Jiang1, Ruihui Liu, Shengshan Dou, Lei Liu, Weidong Zhang, Zhongliang Chen, Ruilin Xu, Jianmi Ding.   

Abstract

A valid method using liquid chromatography coupled with electrospray ionization (ESI) and ion trap mass spectrometry was established for the study of the absorbed components in rat plasma after oral administration of a traditional Chinese medicine (TCM) Shexiang Baoxin pill. The plasma was deproteinated by adding methanol prior to liquid chromatography, in which separation was carried out on a Symmetry C(18) column (5 microm, 250 x 4.6 mm). A linear gradient with 0.5% formic acid-water-acetonitrile was used as mobile phase. Mass spectra were acquired in both negative and positive modes. Twenty-one components including 17 components from Shexiang Baoxin pill and four metabolites were observed from a comprehensive analysis of the chromatography of Shexiang Baoxin pill, controlled plasma and dosed plasma. All of the 17 prototype compounds and three of the metabolites were identified by comparing their retention behaviors and MS and MS/MS spectra with reference compounds and literature data. This study developed an integrated method for screening the bioactive constituents in plasma after oral adminstration of Chinese herbal medicine and provided helpful chemical information for further pharmacology and active mechanism research on TCM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19517427     DOI: 10.1002/bmc.1258

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  7 in total

1.  Shexiang Baoxin Pill, a Proprietary Multi-Constituent Chinese Medicine, Prevents Locomotor and Cognitive Impairment Caused by Brain Ischemia and Reperfusion Injury in Rats: A Potential Therapy for Neuropsychiatric Sequelae of Stroke.

Authors:  Zong-Shi Qin; Yu Zheng; Xi-Dan Zhou; Dong-Dong Shi; Dan Cheng; Chun Shum Shek; Chang-Sen Zhan; Zhang-Jin Zhang
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

2.  Systems Pharmacology Dissecting Holistic Medicine for Treatment of Complex Diseases: An Example Using Cardiocerebrovascular Diseases Treated by TCM.

Authors:  Yonghua Wang; Chunli Zheng; Chao Huang; Yan Li; Xuetong Chen; Ziyin Wu; Zhenzhong Wang; Wei Xiao; Boli Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-26       Impact factor: 2.629

3.  A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases.

Authors:  Hai-Yang Fang; Hua-Wu Zeng; Li-Mei Lin; Xing Chen; Xiao-Na Shen; Peng Fu; Chao Lv; Qun Liu; Run-Hui Liu; Wei-Dong Zhang; Jing Zhao
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

4.  Co-administration of Shexiang Baoxin Pill and Chemotherapy Drugs Potentiated Cancer Therapy by Vascular-Promoting Strategy.

Authors:  Liu-Qing Yang; Ru-Yi Li; Xi-Yan Yang; Qian-Fei Cui; Fei-Yun Wang; Guo-Qiang Lin; Jian-Ge Zhang
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

5.  Metabolomic strategy for studying the intervention and the synergistic effects of the shexiang baoxin pill for treating myocardial infarction in rats.

Authors:  Li Xiang; Peng Jiang; Shuping Wang; Yaohua Hu; Xiaojun Liu; Rongcai Yue; Weidong Zhang; Runhui Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-28       Impact factor: 2.629

6.  Inhibitory effect of cinobufagin on L-type Ca2+ currents, contractility, and Ca2+ homeostasis of isolated adult rat ventricular myocytes.

Authors:  Pinya Li; Qiongtao Song; Tao Liu; Zhonglin Wu; Xi Chu; Xuan Zhang; Ying Zhang; Yonggang Gao; Jianping Zhang; Li Chu
Journal:  ScientificWorldJournal       Date:  2014-05-25

Review 7.  Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases.

Authors:  Li Lu; Xiaodong Sun; Chen Chen; Yating Qin; Xiaomei Guo
Journal:  Front Pharmacol       Date:  2018-11-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.